This is very significant news, but the street may have problems immediately digesting the implications. Omeros has essentially created and released three new classes of medications into the pharma universe, analogous to announcing the discovery of beta-blockers and anti-histamines. It will be interesting to watch how this plays out.
The street is littered with bankrupt companies that failed to monetize their ideas. So I agree that a pharma deal is needed for the street to figure out how much to value the company and it would alleviate cash burn fears.